{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T04:06:55Z","timestamp":1791173215517,"version":"4.1.0"},"reference-count":87,"publisher":"Public Library of Science (PLoS)","issue":"5","license":[{"start":{"date-parts":[[2013,5,15]],"date-time":"2013-05-15T00:00:00Z","timestamp":1368576000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0063201","type":"journal-article","created":{"date-parts":[[2013,5,15]],"date-time":"2013-05-15T21:51:36Z","timestamp":1368654696000},"page":"e63201","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":26,"title":["Recombinant Vaccines against T. gondii: Comparison between Homologous and Heterologous Vaccination Protocols Using Two Viral Vectors Expressing SAG1"],"prefix":"10.1371","volume":"8","author":[{"given":"\u00c9rica Ara\u00fajo","family":"Mendes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flavio G.","family":"Fonseca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00e1rbara M.","family":"Cas\u00e9rio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jana\u00edna P.","family":"Colina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo Tostes","family":"Gazzinelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Braulia C.","family":"Caetano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2013,5,15]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1128\/CMR.11.2.267","article-title":"Structures of Toxoplasma gondii tachyzoites, bradyzoites, and sporozoites and biology and development of tissue cysts","volume":"11","author":"JP Dubey","year":"1998","journal-title":"Clin Microbiol Rev"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.vetpar.2004.09.005","article-title":"Toxoplasmosis - a waterborne zoonosis","volume":"126","author":"JP Dubey","year":"2004","journal-title":"Vet Parasitol"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Tenter AM, Heckeroth AR, Weiss LM (2000) Toxoplasma gondii: from animals to humans. Int J Parasitol. 1217\u20131258.","DOI":"10.1016\/S0020-7519(00)00124-7"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1590\/S0074-02762009000200013","article-title":"Advances in understanding immunity to Toxoplasma gondii","volume":"104","author":"ED Tait","year":"2009","journal-title":"Mem Inst Oswaldo Cruz"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.pt.2011.08.001","article-title":"Toxoplasma gondii effectors are master regulators of the inflammatory response","volume":"27","author":"MB Melo","year":"2011","journal-title":"Trends Parasitol"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1128\/IAI.68.3.1026-1033.2000","article-title":"B cells are essential for vaccination-induced resistance to virulent Toxoplasma gondii","volume":"68","author":"PC Sayles","year":"2000","journal-title":"Infect Immun"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"4054","DOI":"10.1016\/j.vaccine.2004.03.056","article-title":"Vaccination protects B cell-deficient mice against an oral challenge with mildly virulent Toxoplasma gondii","volume":"22","author":"LL Johnson","year":"2004","journal-title":"Vaccine"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1590\/S0074-02762009000200029","article-title":"Why prevent, diagnose and treat congenital toxoplasmosis","volume":"104","author":"R McLeod","year":"2009","journal-title":"Mem Inst Oswaldo Cruz"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/j.1863-2378.2009.01273.x","article-title":"Cats and Toxoplasma: implications for public health","volume":"57","author":"HA Dabritz","year":"2010","journal-title":"Zoonoses Public Health"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S0304-4017(01)00557-X","article-title":"Advances and prospects for subunit vaccines against protozoa of veterinary importance","volume":"101","author":"MC Jenkins","year":"2001","journal-title":"Vet Parasitol"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s00431-005-1665-4","article-title":"Treatment of infants with congenital toxoplasmosis: tolerability and plasma concentrations of sulfadiazine and pyrimethamine","volume":"165","author":"DR Schmidt","year":"2006","journal-title":"Eur J Pediatr"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1590\/S0074-02762009000200019","article-title":"Vaccines against Toxoplasma gondii: challenges and opportunities","volume":"104","author":"E Jongert","year":"2009","journal-title":"Mem Inst Oswaldo Cruz"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.virol.2005.09.020","article-title":"Replication-defective viruses as vaccines and vaccine vectors","volume":"344","author":"T Dudek","year":"2006","journal-title":"Virology"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1586\/14760584.6.3.347","article-title":"T-cell immunity generated by recombinant adenovirus vaccines","volume":"6","author":"TC Yang","year":"2007","journal-title":"Expert Rev Vaccines"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.virusres.2007.10.005","article-title":"Adenovirus vector induced innate immune responses: impact upon efficacy and toxicity in gene therapy and vaccine applications","volume":"132","author":"ZC Hartman","year":"2008","journal-title":"Virus Res"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1089\/hum.2008.141","article-title":"Innate immune recognition of viruses and viral vectors","volume":"20","author":"X Huang","year":"2009","journal-title":"Hum Gene Ther"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1586\/erv.11.121","article-title":"Innate immune recognition of poxviral vaccine vectors","volume":"10","author":"EL Lousberg","year":"2011","journal-title":"Expert Rev Vaccines"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1128\/JVI.01597-10","article-title":"Multiple innate immune pathways contribute to the immunogenicity of recombinant adenovirus vaccine vectors","volume":"85","author":"EG Rhee","year":"2011","journal-title":"J Virol"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"7356","DOI":"10.1128\/IAI.73.11.7356-7365.2005","article-title":"Immune responses against a single CD8+-T-cell epitope induced by virus vector vaccination can successfully control Trypanosoma cruzi infection","volume":"73","author":"Y Miyahira","year":"2005","journal-title":"Infect Immun"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"5368","DOI":"10.1016\/j.vaccine.2008.08.001","article-title":"Efficacy and safety of a live canine adenovirus-vectored rabies virus vaccine in swine","volume":"26","author":"Y Liu","year":"2008","journal-title":"Vaccine"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1097\/COH.0b013e32833cfe4c","article-title":"Novel adenovirus vector-based vaccines for HIV-1","volume":"5","author":"DH Barouch","year":"2010","journal-title":"Curr Opin HIV AIDS"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"e24586","DOI":"10.1371\/journal.pone.0024586","article-title":"Adenovirus 5-vectored P. falciparum vaccine expressing CSP and AMA1. Part A: safety and immunogenicity in seronegative adults","volume":"6","author":"M Sedegah","year":"2011","journal-title":"PLoS One"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"2720","DOI":"10.1016\/j.vaccine.2011.01.083","article-title":"Adenovirus-vectored Plasmodium vivax ookinete surface protein, Pvs25, as a potential transmission-blocking vaccine","volume":"29","author":"T Miyata","year":"2011","journal-title":"Vaccine"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1093\/infdis\/jir842","article-title":"Therapeutic vaccination with recombinant adenovirus reduces splenic parasite burden in experimental visceral leishmaniasis","volume":"205","author":"A Maroof","year":"2012","journal-title":"J Infect Dis"},{"key":"ref25","first-page":"83","article-title":"Recombinant viruses as tools to induce protective cellular immunity against infectious diseases","volume":"7","author":"CD Rocha","year":"2004","journal-title":"Int Microbiol"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/978-1-4419-5632-3_7","article-title":"Strategies and implications for prime-boost vaccination to generate memory CD8 T cells","volume":"780","author":"JC Nolz","year":"2011","journal-title":"Adv Exp Med Biol"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1128\/JVI.06254-11","article-title":"Adenovirus serotype 5 neutralizing antibodies target both hexon and fiber following vaccination and natural infection","volume":"86","author":"RR Bradley","year":"2012","journal-title":"J Virol"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"7179","DOI":"10.4049\/jimmunol.174.11.7179","article-title":"Neutralizing antibodies to adenovirus serotype 5 vaccine vectors are directed primarily against the adenovirus hexon protein","volume":"174","author":"SM Sumida","year":"2005","journal-title":"J Immunol"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"78","DOI":"10.4161\/hv.6.1.10116","article-title":"Prime-boost vectored malaria vaccines: progress and prospects","volume":"6","author":"AV Hill","year":"2010","journal-title":"Hum Vaccin"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.coi.2009.05.016","article-title":"Heterologous prime-boost vaccination","volume":"21","author":"S Lu","year":"2009","journal-title":"Curr Opin Immunol"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1586\/erv.10.106","article-title":"Prime-boost immunization with poxvirus or adenovirus vectors as a strategy to develop a protective vaccine for HIV-1","volume":"9","author":"RM Paris","year":"2010","journal-title":"Expert Rev Vaccines"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"867","DOI":"10.4161\/hv.9693","article-title":"Attenuated poxvirus vectors MVA and NYVAC as promising vaccine candidates against HIV\/AIDS","volume":"5","author":"M Esteban","year":"2009","journal-title":"Hum Vaccin"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"4590","DOI":"10.1073\/pnas.0401165101","article-title":"Highly attenuated smallpox vaccine protects mice with and without immune deficiencies against pathogenic vaccinia virus challenge","volume":"101","author":"LS Wyatt","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1006\/viro.1997.8845","article-title":"Host range and cytopathogenicity of the highly attenuated MVA strain of vaccinia virus: propagation and generation of recombinant viruses in a nonhuman mammalian cell line","volume":"238","author":"MW Carroll","year":"1997","journal-title":"Virology"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S0958-1669(97)80031-6","article-title":"Poxviruses as expression vectors","volume":"8","author":"MW Carroll","year":"1997","journal-title":"Curr Opin Biotechnol"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S0264-410X(96)00195-8","article-title":"Highly attenuated modified vaccinia virus Ankara (MVA) as an effective recombinant vector: a murine tumor model","volume":"15","author":"MW Carroll","year":"1997","journal-title":"Vaccine"},{"key":"ref37","first-page":"1525","article-title":"[Smallpox, an old foe]","volume":"17","author":"HG Schatzmayr","year":"2001","journal-title":"Cad Saude Publica"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"263","DOI":"10.2174\/1568005033481123","article-title":"Vaccinia vectors as candidate vaccines: the development of modified vaccinia virus Ankara for antigen delivery","volume":"3","author":"G Sutter","year":"2003","journal-title":"Curr Drug Targets Infect Disord"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0020-7519(97)00182-3","article-title":"The surface of <italic>Toxoplasma<\/italic>: more and less","volume":"28","author":"JC Boothroyd","year":"1998","journal-title":"Int J Parasitol"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1006\/expr.1994.1054","article-title":"Attachment of Toxoplasma gondii to host cells involves major surface protein, SAG-1 (P30)","volume":"79","author":"JR Mineo","year":"1994","journal-title":"Exp Parasitol"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1590\/S0036-46652010000200001","article-title":"High diagnostic efficiency of IgM-ELISA with the use of multiple antigen peptides (MAP1) from T. gondii ESA (SAG-1, GRA-1 and GRA-7), in acute toxoplasmosis","volume":"52","author":"PR Araujo","year":"2010","journal-title":"Rev Inst Med Trop Sao Paulo"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1745-7580-6-12","article-title":"Human immunome, bioinformatic analyses using HLA supermotifs and the parasite genome, binding assays, studies of human T cell responses, and immunization of HLA-A*1101 transgenic mice including novel adjuvants provide a foundation for HLA-A03 restricted CD8+T cell epitope based, adjuvanted vaccine protective against Toxoplasma gondii","volume":"6","author":"H Cong","year":"2010","journal-title":"Immunome Res"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1089\/hum.2006.17.415","article-title":"Vaccination with replication-deficient recombinant adenoviruses encoding the main surface antigens of toxoplasma gondii induces immune response and protection against infection in mice","volume":"17","author":"BC Caetano","year":"2006","journal-title":"Hum Gene Ther"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"4476","DOI":"10.1016\/j.vaccine.2011.04.044","article-title":"MyD88-dependent protective immunity elicited by adenovirus 5 expressing the surface antigen 1 from Toxoplasma gondii is mediated by CD8(+) T lymphocytes","volume":"29","author":"EA Mendes","year":"2011","journal-title":"Vaccine"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"806","DOI":"10.2307\/3281034","article-title":"Antigenic differences between endozoites and cystozoites of Toxoplasma gondii","volume":"69","author":"MN Lunde","year":"1983","journal-title":"J Parasitol"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1001\/jama.1941.02820090001001","article-title":"Toxoplasmic encephalithes in children","volume":"116","author":"AB Sabin","year":"1941","journal-title":"J Am Med Assoc"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1128\/JCM.38.4.1453-1460.2000","article-title":"Fractionation of membrane components from tachyzoite forms of <italic>Toxoplasma gondii<\/italic>: differential recognition by immunoglobulin M (IgM) and IgG present in sera from patients with acute or chronic toxoplasmosis","volume":"38","author":"M Giraldo","year":"2000","journal-title":"J Clin Microbiol"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"6641","DOI":"10.1073\/pnas.0401939101","article-title":"Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes mice","volume":"101","author":"H Bisht","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1002\/hep.510250236","article-title":"Induction of cytotoxic T-cell response against hepatitis C virus structural antigens using a defective recombinant adenovirus","volume":"25","author":"O Bruna-Romero","year":"1997","journal-title":"Hepatology"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/0169-4758(94)90026-4","article-title":"Attachment and invasion of host cells by Toxoplasma gondii","volume":"10","author":"LH Kasper","year":"1994","journal-title":"Parasitol Today"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"3977","DOI":"10.1016\/j.vaccine.2010.03.028","article-title":"Identification of T. gondii epitopes, adjuvants, and host genetic factors that influence protection of mice and humans","volume":"28","author":"TG Tan","year":"2010","journal-title":"Vaccine"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1086\/315186","article-title":"Immunization with a DNA plasmid encoding the SAG1 (P30) protein of <italic>Toxoplasma gondii<\/italic> is immunogenic and protective in rodents","volume":"181","author":"CW Angus","year":"2000","journal-title":"J Infect Dis"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1128\/IAI.69.3.1605-1612.2001","article-title":"Intranasal immunization with SAG1 and nontoxic mutant heat-labile enterotoxins protects mice against <italic>Toxoplasma gondii<\/italic>","volume":"69","author":"C Bonenfant","year":"2001","journal-title":"Infect Immun"},{"key":"ref54","first-page":"1448","article-title":"Protective effect of DNA-mediated immunization with a combination of SAG1 and IL-2 gene adjuvant against infection of <italic>Toxoplasma gondii<\/italic> in mice","volume":"115","author":"G Chen","year":"2002","journal-title":"Chin Med J (Engl)"},{"key":"ref55","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1016\/j.vaccine.2009.12.005","article-title":"Construction and immunogenicity of pseudotype baculovirus expressing Toxoplasma gondii SAG1 protein in BALB\/c mice model","volume":"28","author":"R Fang","year":"2010","journal-title":"Vaccine"},{"key":"ref56","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.3748\/wjg.v12.i15.2363","article-title":"Biological role of surface Toxoplasma gondii antigen in development of vaccine","volume":"12","author":"KY Liu","year":"2006","journal-title":"World J Gastroenterol"},{"key":"ref57","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.rvsc.2010.01.007","article-title":"The protective effect of a Toxoplasma gondii SAG1 plasmid DNA vaccine in mice is enhanced with IL-18","volume":"89","author":"Q Liu","year":"2010","journal-title":"Res Vet Sci"},{"key":"ref58","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1159\/000207194","article-title":"TRIF, and TRIF-interacting TLRs differentially modulate several adenovirus vector-induced immune responses","volume":"1","author":"DM Appledorn","year":"2009","journal-title":"J Innate Immun"},{"key":"ref59","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.4049\/jimmunol.181.3.2134","article-title":"Adenovirus vector-induced innate inflammatory mediators, MAPK signaling, as well as adaptive immune responses are dependent upon both TLR2 and TLR9 in vivo","volume":"181","author":"DM Appledorn","year":"2008","journal-title":"J Immunol"},{"key":"ref60","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/nature06664","article-title":"The inflammasome recognizes cytosolic microbial and host DNA and triggers an innate immune response","volume":"452","author":"DA Muruve","year":"2008","journal-title":"Nature"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"e18526","DOI":"10.1371\/journal.pone.0018526","article-title":"Pre-existing adenovirus immunity modifies a complex mixed Th1 and Th2 cytokine response to an Ad5\/HIV-1 vaccine candidate in humans","volume":"6","author":"SO Pine","year":"2011","journal-title":"PLoS One"},{"key":"ref62","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1128\/JVI.06165-11","article-title":"Adenovirus serotype 5-specific neutralizing antibodies target multiple hexon hypervariable regions","volume":"86","author":"RR Bradley","year":"2012","journal-title":"J Virol"},{"key":"ref63","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1002\/jmv.21721","article-title":"The prevalence of antibodies to adenovirus serotype 5 in an adult Indian population and implications for adenovirus vector vaccines","volume":"82","author":"R Pilankatta","year":"2010","journal-title":"J Med Virol"},{"key":"ref64","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1038\/mt.2009.130","article-title":"New insights on adenovirus as vaccine vectors","volume":"17","author":"MO Lasaro","year":"2009","journal-title":"Mol Ther"},{"key":"ref65","doi-asserted-by":"crossref","first-page":"4407","DOI":"10.1073\/pnas.91.10.4407","article-title":"Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy","volume":"91","author":"Y Yang","year":"1994","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref66","doi-asserted-by":"crossref","first-page":"2564","DOI":"10.4049\/jimmunol.155.5.2564","article-title":"Clearance of adenovirus-infected hepatocytes by MHC class I-restricted CD4+ CTLs in vivo","volume":"155","author":"Y Yang","year":"1995","journal-title":"J Immunol"},{"key":"ref67","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1128\/JVI.78.6.2666-2673.2004","article-title":"Neutralizing antibodies and CD8+ T lymphocytes both contribute to immunity to adenovirus serotype 5 vaccine vectors","volume":"78","author":"SM Sumida","year":"2004","journal-title":"J Virol"},{"key":"ref68","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1172\/JCI60202","article-title":"Human adenovirus-specific T cells modulate HIV-specific T cell responses to an Ad5-vectored HIV-1 vaccine","volume":"122","author":"N Frahm","year":"2012","journal-title":"J Clin Invest"},{"key":"ref69","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1093\/infdis\/jiq161","article-title":"Effect of preexisting immunity to adenovirus on transgene product-specific genital T cell responses on vaccination of mice with a homologous vector","volume":"203","author":"LH Haut","year":"2011","journal-title":"J Infect Dis"},{"key":"ref70","doi-asserted-by":"crossref","first-page":"215","DOI":"10.2174\/156652306776359478","article-title":"Current strategies and future directions for eluding adenoviral vector immunity","volume":"6","author":"DS Bangari","year":"2006","journal-title":"Curr Gene Ther"},{"key":"ref71","doi-asserted-by":"crossref","first-page":"e31177","DOI":"10.1371\/journal.pone.0031177","article-title":"Pre-clinical evaluation of a replication-competent recombinant adenovirus serotype 4 vaccine expressing influenza h5 hemagglutinin","volume":"7","author":"J Alexander","year":"2012","journal-title":"PLoS One"},{"key":"ref72","doi-asserted-by":"crossref","first-page":"8621","DOI":"10.1128\/JVI.76.17.8621-8631.2002","article-title":"Modulation of adenovirus vector tropism via incorporation of polypeptide ligands into the fiber protein","volume":"76","author":"N Belousova","year":"2002","journal-title":"J Virol"},{"key":"ref73","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1128\/JVI.01896-07","article-title":"Modification of adenovirus capsid with a designed protein ligand yields a gene vector targeted to a major molecular marker of cancer","volume":"82","author":"N Belousova","year":"2008","journal-title":"J Virol"},{"key":"ref74","doi-asserted-by":"crossref","first-page":"4554","DOI":"10.1016\/j.vaccine.2005.08.048","article-title":"Synergistic DNA-MVA prime-boost vaccination regimes for malaria and tuberculosis","volume":"24","author":"SC Gilbert","year":"2006","journal-title":"Vaccine"},{"key":"ref75","doi-asserted-by":"crossref","first-page":"3124","DOI":"10.1016\/j.vaccine.2011.02.051","article-title":"Partial efficacy of a VSV-SIV\/MVA-SIV vaccine regimen against oral SIV challenge in infant macaques","volume":"29","author":"ML Marthas","year":"2011","journal-title":"Vaccine"},{"key":"ref76","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1128\/CVI.00006-10","article-title":"Highly persistent and effective prime\/boost regimens against tuberculosis that use a multivalent modified vaccine virus Ankara-based tuberculosis vaccine with interleukin-15 as a molecular adjuvant","volume":"17","author":"K Kolibab","year":"2010","journal-title":"Clin Vaccine Immunol"},{"key":"ref77","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1016\/j.vaccine.2010.12.016","article-title":"Immunization with recombinant DNA and modified vaccinia virus Ankara (MVA) vectors delivering PSCA and STEAP1 antigens inhibits prostate cancer progression","volume":"29","author":"M Krupa","year":"2011","journal-title":"Vaccine"},{"key":"ref78","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1038\/mt.2012.25","article-title":"Mixed vector immunization with recombinant adenovirus and MVA can improve vaccine efficacy while decreasing antivector immunity","volume":"20","author":"A Reyes-Sandoval","year":"2012","journal-title":"Mol Ther"},{"key":"ref79","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1111\/j.1365-3024.2009.01146.x","article-title":"Major role for CD8 T cells in the protection against Toxoplasma gondii following dendritic cell vaccination","volume":"31","author":"R Guiton","year":"2009","journal-title":"Parasite Immunol"},{"key":"ref80","doi-asserted-by":"crossref","first-page":"4254","DOI":"10.4049\/jimmunol.170.8.4254","article-title":"TCR V beta 8+ T cells prevent development of toxoplasmic encephalitis in BALB\/c mice genetically resistant to the disease","volume":"170","author":"H Kang","year":"2003","journal-title":"J Immunol"},{"key":"ref81","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1089\/jir.2005.25.338","article-title":"Importance of CD8(+)Vbeta8(+) T cells in IFN-gamma-mediated prevention of toxoplasmic encephalitis in genetically resistant BALB\/c mice","volume":"25","author":"X Wang","year":"2005","journal-title":"J Interferon Cytokine Res"},{"key":"ref82","doi-asserted-by":"crossref","first-page":"10661","DOI":"10.1128\/JVI.00056-12","article-title":"HIV controllers maintain a population of highly efficient Th1 effector cells in contrast to patients treated in the long term","volume":"86","author":"B Vingert","year":"2012","journal-title":"J Virol"},{"key":"ref83","doi-asserted-by":"crossref","first-page":"e38859","DOI":"10.1371\/journal.pone.0038859","article-title":"High quality long-term CD4+ and CD8+ effector memory populations stimulated by DNA-LACK\/MVA-LACK regimen in Leishmania major BALB\/c model of infection","volume":"7","author":"L Sanchez-Sampedro","year":"2012","journal-title":"PLoS One"},{"key":"ref84","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1084\/jem.20062363","article-title":"Immunization with vaccinia virus induces polyfunctional and phenotypically distinctive CD8(+) T cell responses","volume":"204","author":"ML Precopio","year":"2007","journal-title":"J Exp Med"},{"key":"ref85","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1128\/IAI.00740-09","article-title":"Prime-boost immunization with adenoviral and modified vaccinia virus Ankara vectors enhances the durability and polyfunctionality of protective malaria CD8+ T-cell responses","volume":"78","author":"A Reyes-Sandoval","year":"2010","journal-title":"Infect Immun"},{"key":"ref86","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.2353\/ajpath.2010.090825","article-title":"Removal of Toxoplasma gondii cysts from the brain by perforin-mediated activity of CD8+ T cells","volume":"176","author":"Y Suzuki","year":"2010","journal-title":"Am J Pathol"},{"key":"ref87","doi-asserted-by":"crossref","first-page":"11007","DOI":"10.1128\/JVI.05346-11","article-title":"Durable mucosal simian immunodeficiency virus-specific effector memory T lymphocyte responses elicited by recombinant adenovirus vectors in rhesus monkeys","volume":"85","author":"H Li","year":"2011","journal-title":"J Virol"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0063201","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T19:45:06Z","timestamp":1688240706000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0063201"}},"subtitle":[],"editor":[{"given":"Mauricio Martins","family":"Rodrigues","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2013,5,15]]},"references-count":87,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2013,5,15]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0063201","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,5,15]]}}}